Lupus nephritis
Drug research and approvals for lupus nephritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 87 studies of lupus nephritis are recruiting on ClinicalTrials.gov, Health Canada has authorized 15 drug trials for it since 2013, FDA has 0 approved and 3 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 87
- Trials authorized in Canada: 15
- FDA orphan approvals: 0
- EU medicines: 1
- Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort StudyNCT07931170 · Not reported · Pediatric Nephrology Research Consortium · starts Oct 1, 2026
- Pakistan Arthritis and Connective Tissue Disease Network - Systemic Lupus ErythematosusNCT07902622 · Not reported · Foundation University Islamabad · starts Mar 1, 2025
- HEALTH Home Urinalysis TestingNCT07823478 · Not applicable · NYU Langone Health · starts Sep 8, 2026
- Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With…NCT07799116 · Phase 1 / Phase 2 · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · starts Sep 23, 2026
- Lupus Nephritis Care PathwayNCT07783152 · Not applicable · Duke University · starts Oct 14, 2026
- Assessing Residual Inflammation and Macrophage Presence in Lupus Nephritis After 3 Months of Intensified Treatment With…NCT07760480 · Phase 4 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · starts Apr 23, 2026
- Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)NCT07719140 · Phase 4 · Peking Union Medical College Hospital · starts Jul 1, 2026
- The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis PopulationNCT07700940 · Phase 4 · Ahmed Yehia Ismail · starts Jan 22, 2024
- Biomarker Development for Autoimmune Disorders Involving the KidneysNCT07666711 · Not reported · Oslo University Hospital · starts Jun 15, 2026
Approved 2
- VoclosporinSerine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor
- BelimumabTumor necrosis factor ligand superfamily member 13B inhibitor
Phase 3 12 of 18
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- PrednisoneGlucocorticoid receptor agonist
- CyclophosphamideDNA inhibitor
- AzathioprineAmidophosphoribosyltransferase inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- AcetaminophenCyclooxygenase inhibitor
- RituximabB-lymphocyte antigen CD20 binding agent
- ObinutuzumabB-lymphocyte antigen CD20 binding agent
- DiphenhydramineHistamine H1 receptor antagonist
- AbataceptT-lymphocyte activation antigen CD86 inhibitor
- AtaciceptTumor necrosis factor ligand superfamily member 13B inhibitor
- LeflunomideDihydroorotate dehydrogenase inhibitor
Phase 2 12 of 24
- BIIB-023Tumor necrosis factor ligand superfamily member 12 inhibitor
- EtanerceptTNF-alpha inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- IptacopanComplement factor B inhibitor
- DaratumumabLymphocyte differentiation antigen CD38 inhibitor
- RuplizumabCD40 ligand inhibitor
- SirukumabInterleukin-6 inhibitor
- GuselkumabInterleukin-23 inhibitor
- ZanubrutinibTyrosine-protein kinase BTK inhibitor
- TamibaroteneRetinoic acid receptor beta agonist
- IguratimodMacrophage migration inhibitory factor inhibitor
- IscalimabTumor necrosis factor receptor superfamily member 5 inhibitor
Phase 1 or earlier 5
- Fludarabine
- DapagliflozinSodium/glucose cotransporter 2 inhibitor
- Ixazomib26S proteasome inhibitor
- FelzartamabLymphocyte differentiation antigen CD38 inhibitor
- Gusperimus
How its trials ended
255 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 60 whose ending is known, 25% met their primary endpoint, 8% missed it and 67% stopped early.
- Ongoing8935%
- Completed, result not reported6224%
- Status unknown4417%
- Stopped: other or unclear187%
- Met its primary endpoint156%
- Stopped: enrollment or feasibility73%
- Stopped: sponsor or business decision62%
- Missed its primary endpoint52%
- Stopped: lack of efficacy52%
- Stopped: safety31%
- Stopped: funding1<1%
| May 14, 2025 | A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate efficacy, safety, pharmacokinetics (PK) and…Ianalumab (VAY736) | Novartis Pharmaceuticals | Pending |
| Dec 17, 2024 | A phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus…YTB323 (rapcabtagene autoleucel) / Fludarabine phosphate / Cyclophosphamide | Novartis Pharmaceuticals | Pending |
| Nov 9, 2023 | An open label phase 1b study of felzartamab in lupus nephritisFelzartamab (HIB202) | Human Immunology Biosciences, Inc. (Hi-Bio) | Ongoing |
| Dec 12, 2022 | A phase 3 randomized, double-blind, placebo-controlled multicenter, multinational study to evaluate the efficacy and safety of atacicept in subjects with…Atacicept (VT-001) / Mycophenolate mofetil | Vera Therapeutics | Pending |
| May 6, 2022 | A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top…VAY736 / Cellcept / Myfortic | Novartis Pharmaceuticals | Ongoing |
| Aug 6, 2021 | A phase II, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab in…Gazyva / Myfenax | Roche | Ongoing |
| Jan 27, 2021 | A phase 2 randomized, double-blind, multicenter study to evaluate the safety and efficacy of oral rilzabrutinib compared to placebo in adult patients with…Rilzabrutinib (PRN1008) / Mycophenolate | Principia Biopharma | Pending |
| Dec 11, 2020 | A phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of ravulizumab in adult participants with proliferative lupus…Ravulizumab | AstraZeneca Pharmaceuticals | Ongoing |
| May 15, 2020 | A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of obinutuzumab in patients with isn/rps 2003…Gazyva (obinutuzumab) / Myfenax (mycophenolate mofetil) | Roche | Closed |
| Apr 1, 2020 | A two-year, phase III randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c.…Cosentyx | Novartis Pharmaceuticals | Closed |
| Jul 28, 2000 | AbetimusTreatment of lupus nephritis. | La Jolla Pharmaceutical Co. | Designated |
| Feb 3, 1998 | BindaritTreatment of lupus nephritis. | Angelini Pharmaceuticals, Inc. | Designated |
| Jan 7, 1993 | Monoclonal antibody for immunization against lupus nephritisTreatment of lupus nephritis. | VivoRx Autoimmune, Inc. | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Sep 15, 2022 | LupkynisVoclosporin | Otsuka Pharmaceutical Netherlands B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA